Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jared Weiss is an Associate Professor of Clinical Research for Hematology/Oncology at the University of North Carolina School of Medicine in Chapel Hill, NC. He completed fellowship in Hematology and Oncology at the University of Pennsylvania and residency in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, MA. He received his Doctor of Medicine at Yale University School of Medicine in New Haven, CT and his B.S. in neuroscience at Brown University, in Providence, RI.

GRACE Targeted Therapies in Lung Cancer 2021 - Diagnosis and Testing: What Tests Are Relevant
dbrock
GRACE Targeted Therapies in Lung Cancer 2021 - Diagnosis and Testing: What Tests Are Relevant
Author
Jared Weiss, MD
Image
Targeted Therapies Patient Forum 2021
The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time.

For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty.  For a first glance at the full playlist of videos, visit the event on our YouTube channel. 

YOUTUBE PLAYLIST

 

In this video, the AM panel of oncologists, with Drs. Weiss, Dagogo-Jack, and Thompson discuss diagnosis and testing: what tests are relevant for what diagnosis. 

A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech

AstraZeneca, Novartis, Lilly, Blueprint Medicines, Takeda Oncology, Boehringer Ingelheim, Genentech

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on